About Index Trending news
Analyze
Pricing
Celgene Corporation

Celgene Corporation

Celgene Corporation

Global biopharmaceutical company. Tweets by Greg Geissman & Julissa Viana. Review our guidelines on our site

Elsewhere

Contributors to this profile

Alexa global traffic share

Twitter followers

Employees

Team size

5000+
Locations
HQ
Headquarters
Xconomy

Immunotherapy Safety Worries Halt Celgene Myeloma Study, Slow 5 Others

Health Science
Xconomy

Celgene Narrows Its Relationship With Sutro, No Acquisition Coming

Health
Xconomy

With FDA Nod, Agios, Celgene Get Speedy OK For Blood Cancer Drug

Health
Xconomy

Celgene Builds Up Cancer Drug Pipeline With BeiGene Deal

Health
Xconomy

Dragonfly, Tyler Jacks’s Disney-Backed Startup, Gets $33M in Celgene Deal

Health
Xconomy

Drug-Hunting Startup From Scripps Attracts Celgene Alum, $50M Backing

Science
$300,000,000
GEN , Xconomy , businesswire

Celgene Buys Delinia for $300M to Acquire Treg Therapy for Autoimmune Diseases Genetic Engineering & Biotechnology News - Biotech from Bench to Business

Xconomy

Celgene Pays Anokion $45M for Autoimmune Research, Option to Buy

Science Funding Health
Xconomy

Acetylon Crafts New Buyout Deal With Celgene, Spins Out Startup Regenacy

Health Strategy
Xconomy

Celgene Touts Data From Early Study of Oral GI Drug

Health
Xconomy

Celgene Plots Speedy FDA Filing for Agios Blood Cancer Drug

Health Science
Xconomy

Celgene Passes on Acetylon as Another Option-to-Buy Deal Flames Out

Health Strategy
Xconomy

With Celgene Deal, Jounce Lands $261M And a “Trusting Partner”

Health
The Motley Fool

When Will Gilead Sciences, Celgene, and CVS Health Hit $100 Again?

The Motley Fool

3 Biotech Stocks to Buy Now for the Long Haul

The Motley Fool

Better Buy: Biogen Inc. vs. Celgene Corporation

The Motley Fool

Better Buy: Ziopharm Oncology, Inc. vs. Celgene

The Motley Fool

3 Stocks on Our Radar

Stock markets Earnings
Xconomy

Agios, Celgene Jump into Immuno-Oncology in Revamped Alliance

Health
The Motley Fool

Big Drugmakers Were Key to Juno Therapeutics' Q1 Performance